Topics

Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah

18:33 EDT 11 Sep 2019 | Elsevier Business Intelligence

Novartis has managed to temporarily overcome payer reservations about the real-world value of Kymriah by engaging early with ...

Original Article: Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah

NEXT ARTICLE

More From BioPortfolio on "Early Engagement On Outcomes-Based Deals Helps Unlock EU Access To Kymriah"

Quick Search

Relevant Topic

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...